Evidence map›Paper›PMID 38285206›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Determining the optimal pharmacokinetic modelling and simplified quantification method of [

Ruiyue Zhao, Zeheng Xia, Miao Ke, Jie Lv, Huizhen Zhong, Yulu He, Di Gu, Yongda Liu, Guohua Zeng, Lin Zhu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruiyue Zhao *Department of Nuclear Medicine, The Key Laboratory of Advanced Interdisciplinary Studies Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.ORCID 0000-0001-5242-0785
Zeheng Xia *Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China.
Miao Ke *Department of Nuclear Medicine, The Key Laboratory of Advanced Interdisciplinary Studies Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Jie LvDepartment of Nuclear Medicine, The Key Laboratory of Advanced Interdisciplinary Studies Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Huizhen ZhongDepartment of Nuclear Medicine, The Key Laboratory of Advanced Interdisciplinary Studies Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Yulu HeDepartment of Nuclear Medicine, The Key Laboratory of Advanced Interdisciplinary Studies Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Di GuDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Yongda LiuDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Guohua ZengDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Lin ZhuDepartment of Nuclear Medicine, The Key Laboratory of Advanced Interdisciplinary Studies Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
David AlexoffFive Eleven Pharma Inc., 3700 Market St., Philadelphia, PA, 19104, USA.
Hank F KungFive Eleven Pharma Inc., 3700 Market St., Philadelphia, PA, 19104, USA.
Xinlu WangDepartment of Nuclear Medicine, The Key Laboratory of Advanced Interdisciplinary Studies Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China. 71lu@163.com.
Tao SunShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China. tao.sun@siat.ac.cn.

Funding

Cultivation Fund of the Key Scientific and Technical Innovation Project, Ministry of Education GJJSTD20180002Department of Science and Technology of Guangdong Province 2022A1515110716Guangdong regional joint fund 2022A1515110941Guangzhou basic and applied basic research 2023A04J1196Science and technology program of Guangzhou 202201020558Shenzhen Science and Technology Innovation Committee 20220531100209020the Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province 2023B1212060052
6 · The paper itself

Abstract

purposeThis paper discusses the optimization of pharmacokinetic modelling and alternate simplified quantification method for [

methodsDynamic PET/CT scans were conducted on eight primary prostate cancer patients, followed by a whole-body scan at 60 min post-injection. Time-activity curves (TACs) were obtained by drawing volumes of interest for primary prostatic and metastatic lesions. Optimal kinetic modelling involved evaluating three compartmental models (1T2K, 2T3K, and 2T4K) accounting for fractional blood volume (V

resultsIn total, 17 intraprostatic lesions, 10 lymph nodes, and 36 osseous metastases were evaluated. Visually, the contrast of the tumor increased and showed the steepest incline within the first few minutes, whereas background activity decreased over time. Full pharmacokinetic analysis revealed that a reversible two-compartmental (2T4K) model is the preferred kinetic model for the given tracer. The kinetic parameters K

conclusionsThis study introduced an optimized pharmacokinetic modelling approach and a simplified acquisition method for [

Indexed as

Models, BiologicalPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedHumansKineticsLysineMaleMiddle AgedRadiopharmaceuticalsUrea2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidLysineRadiopharmaceuticalsUrea[18F]AlF-P16-093Dynamic PETPharmacokinetic modellingPrimary prostate cancerPSMA

Identifiers

PMID38285206

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.